Device Description : MTS™ (MIC Test Strip) Levofloxacin 0.002-32 μg/mL is a quantitative method inten (View more) MTS™ (MIC Test Strip) Levofloxacin 0.002-32 μg/mL is a quantitative method intended for the in vitro determination of antimicrobial susceptibility of bacteria. MTS™ consists of specialized paper impregnated with a pre-defined concentration gradient of an antimicrobial agent, which is used to determine the minimum inhibitory concentration (MIC) in μg/mL of antimicrobial agents against bacteria as tested on agar media using overnight incubation and manual reading procedures.MTS™ Levofloxacin at concentrations of 0.002-32 μg/mL should be interpreted at 16-20 hours of incubation.MTS™ Levofloxacin can be used to determine the MIC of levofloxacin against the following bacteria.Levofloxacin has been shown to be active both clinically and in vitro against these bacterial species according to the FDA drug approved label:Gram-negative bacteriaEnterobacter cloacaeEscherichia coliKlebsiella pneumoniaeProteus mirabilisPseudomonas aeruginosaSerratia marcescensLevofloxacin has been shown to be active in vitro only against the non-fastidious bacteria listed below according to the FDA drug approved label:Citrobacter freundiiCitrobacter koseriKlebsiella aerogenesKlebsiella oxytocaMorganella morganiiProteus vulgarisProvidencia rettgeriProvidencia stuartii (View less)

Device Description : MTS™ (MIC Test Strip) Levofloxacin 0.002-32 μg/mL is a quantitative method inten (View more) MTS™ (MIC Test Strip) Levofloxacin 0.002-32 μg/mL is a quantitative method intended for the in vitro determination of antimicrobial susceptibility of bacteria. MTS™ consists of specialized paper impregnated with a pre-defined concentration gradient of an antimicrobial agent, which is used to determine the minimum inhibitory concentration (MIC) in μg/mL of antimicrobial agents against bacteria as tested on agar media using overnight incubation and manual reading procedures.MTS™ Levofloxacin at concentrations of 0.002-32 μg/mL should be interpreted at 16-20 hours of incubation.MTS™ Levofloxacin can be used to determine the MIC of levofloxacin against the following bacteria.Levofloxacin has been shown to be active both clinically and in vitro against these bacterial species according to the FDA drug approved label:Gram-negative bacteriaEnterobacter cloacaeEscherichia coliKlebsiella pneumoniaeProteus mirabilisPseudomonas aeruginosaSerratia marcescensLevofloxacin has been shown to be active in vitro only against the non-fastidious bacteria listed below according to the FDA drug approved label:Citrobacter freundiiCitrobacter koseriKlebsiella aerogenesKlebsiella oxytocaMorganella morganiiProteus vulgarisProvidencia rettgeriProvidencia stuartii (View less)

Device Description : MTS is a quantitative assay for determining the Minimum Inhibitory Concentration (View more) MTS is a quantitative assay for determining the Minimum Inhibitory Concentration (M.I.C.) of antimicrobial agents against microorganisms. Liofilchem MIC Test Strip Penicillin G 0.002-32 µg/mL are specialized strips impregnated with a predefined concentration gradient of Penicillin G for susceptibility testing of Streptococcus ssp. (View less)

Device Description : MTS is a quantitative assay for determining the Minimum Inhibitory Concentration (View more) MTS is a quantitative assay for determining the Minimum Inhibitory Concentration (M.I.C.) of antimicrobial agents against microorganisms. Liofilchem MIC Test Strip Penicillin G 0.002-32 µg/mL are specialized strips impregnated with a predefined concentration gradient of Penicillin G for susceptibility testing of Streptococcus ssp. (View less)

Device Description : The Liofilchem® MTS™ (MIC Test Strip) Eravacycline 0.002-32 µg/mL is a quantitat (View more) The Liofilchem® MTS™ (MIC Test Strip) Eravacycline 0.002-32 µg/mL is a quantitative method intended for the in vitro determination of antimicrobial susceptibility ofbacteria. MTS™ consists of specialized paper impregnated with a pre-defined concentration gradient of an antimicrobial agent, which is used todetermine the minimum inhibitory concentration (MIC) in µglmL of antimicrobial agents against bacteria as tested on agar media using ovemightincubation and manual reading procedures. The MTS™ Eravacycline at concentrations of 0.002-32 µglmL should be interpreted at 16-20 hours ofincubation.MTS™ Eravacycline can be used to dete1mine the MIC of eravacycline against the following bacteria.Eravacycline has been shown to be active both clinically and in vitro against these bacterial species accoring to the FDA drug approved label:Gram-positive bacteriaEnterococcus faecalisEnterococcus faeciumStaphylococcus aureusGram-negative bacteriaCitrobacter freundiiEnterobacter cloacaeEscherichia coliKlebsiella oxytocaKlebsiella pneumoniaeEravacycline has been shown to be active in vitro only against the non-fastidious bacteria listed below accoring to the FDA drug aprroved label:Citrobacter koseriKlebsiella (Enterobacter) aerogenes (View less)

Device Description : The Liofilchem® MTS™ (MIC Test Strip) Eravacycline 0.002-32 µg/mL is a quantitat (View more) The Liofilchem® MTS™ (MIC Test Strip) Eravacycline 0.002-32 µg/mL is a quantitative method intended for the in vitro determination of antimicrobial susceptibility ofbacteria. MTS™ consists of specialized paper impregnated with a pre-defined concentration gradient of an antimicrobial agent, which is used todetermine the minimum inhibitory concentration (MIC) in µglmL of antimicrobial agents against bacteria as tested on agar media using ovemightincubation and manual reading procedures. The MTS™ Eravacycline at concentrations of 0.002-32 µglmL should be interpreted at 16-20 hours ofincubation.MTS™ Eravacycline can be used to dete1mine the MIC of eravacycline against the following bacteria.Eravacycline has been shown to be active both clinically and in vitro against these bacterial species accoring to the FDA drug approved label:Gram-positive bacteriaEnterococcus faecalisEnterococcus faeciumStaphylococcus aureusGram-negative bacteriaCitrobacter freundiiEnterobacter cloacaeEscherichia coliKlebsiella oxytocaKlebsiella pneumoniaeEravacycline has been shown to be active in vitro only against the non-fastidious bacteria listed below accoring to the FDA drug aprroved label:Citrobacter koseriKlebsiella (Enterobacter) aerogenes (View less)

Device Description : The MTS™ Tetracycline 0.016-256 μg/mL is a quantitative method intended for the (View more) The MTS™ Tetracycline 0.016-256 μg/mL is a quantitative method intended for the in vitro determination of antimicrobial susceptibility of bacteria. MTS™ consists of specialized paper impregnated with a pre-defined concentration gradient of an antimicrobial agent, which is used to determine the minimum inhibitory concentration (MIC) in μg/mL of antimicrobial agents against bacteria as tested on agar media using overnight incubation and manual reading procedures. The MTS™ Tetracycline at concentrations of 0.016-256 μg/mL should be interpreted at 16-20 hours of incubation.Tetracycline has been shown to be active both clinically and in vitro against these bacterial species according to the FDA drug approved label:Staphylococcus aureusAcinetobacter baumanniiEscherichia coliKlebsiella aerogenesKlebsiella oxytocaKlebsiella pneumoniae (View less)

Device Description : The MTS™ Tetracycline 0.016-256 μg/mL is a quantitative method intended for the (View more) The MTS™ Tetracycline 0.016-256 μg/mL is a quantitative method intended for the in vitro determination of antimicrobial susceptibility of bacteria. MTS™ consists of specialized paper impregnated with a pre-defined concentration gradient of an antimicrobial agent, which is used to determine the minimum inhibitory concentration (MIC) in μg/mL of antimicrobial agents against bacteria as tested on agar media using overnight incubation and manual reading procedures. The MTS™ Tetracycline at concentrations of 0.016-256 μg/mL should be interpreted at 16-20 hours of incubation.Tetracycline has been shown to be active both clinically and in vitro against these bacterial species according to the FDA drug approved label:Staphylococcus aureusAcinetobacter baumanniiEscherichia coliKlebsiella aerogenesKlebsiella oxytocaKlebsiella pneumoniae (View less)